Filtered By:
Cancer: Adenocarcinoma
Therapy: Corticosteroid Therapy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 72 results found since Jan 2013.
Recurrent Transient Asymptomatic Pulmonary Opacity with Long-Term Afatinib: A Case Report
Case Rep Oncol. 2023 Mar 28;16(1):167-171. doi: 10.1159/000529894. eCollection 2023 Jan-Dec.ABSTRACTAfatinib is the second generation EGFR-TKI. Recently, transient asymptomatic pulmonary opacity (TAPO) was reported in EGFR-mutation harboring NSCLC receiving osimertinib. However, TAPO related to other EGFR-TKI has not been reported. Here, we reported a case of TAPO related to afatinib in lung adenocarcinoma harboring EGFR mutation. A 64-year-old male had the diagnosis of stage IV (The 7th edition of the staging system by the Union for International Cancer Control) lung adenocarcinoma harboring EGFR del 19 mutation. He recei...
Source: Cancer Control - April 3, 2023 Category: Cancer & Oncology Authors: Keisuke Watanabe Nobuaki Kobayashi Takeshi Kaneko Source Type: research
Highlights into historical and current immune interventions for cancer
Int Immunopharmacol. 2023 Feb 27;117:109882. doi: 10.1016/j.intimp.2023.109882. Online ahead of print.ABSTRACTImmunotherapy is an additional pillar when combined with traditional standards of care such as chemotherapy, radiotherapy, and surgery for cancer patients. It has revolutionized cancer treatment and rejuvenated the field of tumor immunology. Several types of immunotherapies, including adoptive cellular therapy (ACT) and checkpoint inhibitors (CPIs), can induce durable clinical responses. However, their efficacies vary, and only subsets of cancer patients benefit from their use. In this review, we address three goal...
Source: International Immunopharmacology - February 27, 2023 Category: Allergy & Immunology Authors: Kathryn Cole Zaid Al-Kadhimi James E Talmadge Source Type: research
Osimertinib-Induced Cutaneous Vasculitis Responsive to Low-Dose Dapsone Without Interruption of Anticancer Therapy: A Case Report and Review of the Literature
JTO Clin Res Rep. 2022 Sep 21;3(11):100415. doi: 10.1016/j.jtocrr.2022.100415. eCollection 2022 Nov.ABSTRACTA 45-year-old woman with a history of lung adenocarcinoma treated with osimertinib developed purpuric plaques and vesicles on the lower extremities after 5 months of therapy. Skin biopsy revealed leukocytoclastic vasculitis (LCV). A workup for systemic involvement was unremarkable. The patient was treated with oral dapsone while continuing osimertinib without interruption. Skin lesions cleared within 2 weeks of therapy with no recurrence after titrating off dapsone. To the best of our knowledge, this is the first rep...
Source: Clinical Lung Cancer - October 24, 2022 Category: Cancer & Oncology Authors: Christopher Iriarte Jonathan H Young Michael S Rabin Nicole R LeBoeuf Source Type: research
Chronic urticaria associated with lung adenocarcinoma - a paraneoplastic manifestation: A case report and literature review
CONCLUSION: Chronic spontaneous urticaria is considered a paraneoplastic dermatosis with a controversial association in the literature. In the presented case, a young patient presented with chronic refractory urticaria and after an exhaustive clinical work-up was found to have a diagnosis of poorly differentiated lung adenocarcinoma with high expression of TTF-1. According to the Curth criteria, the urticaria presented by the patient is related to the oncological diagnosis. In addition, the high expression of TTF-1 documented in this case could be acting as an autoantigen that would cause chronic spontaneous urticaria. Fur...
Source: Clinical Lung Cancer - September 26, 2022 Category: Cancer & Oncology Authors: Luisa Fernanda Jim énez Evis Adriana Castell ón Juan David Marenco Jos é Maria Mejía Camilo Andr és Rojas Franklin Torres Jim énez Linda Coronell Estefanie Osorio-Llanes Evelyn Mendoza-Torres Source Type: research
Tumor-related cytokine release syndrome in a treatment-naive patient with lung adenocarcinoma: A case report
CONCLUSION: CRS can develop in treatment-naïve lung cancer patients. Patients with tumor-related CRS may be at risk of CRS recurrence, aggravation, and onset of immune checkpoint inhibitor-related adverse events.PMID:35211595 | PMC:PMC8855264 | DOI:10.12998/wjcc.v10.i5.1580
Source: Clinical Lung Cancer - February 25, 2022 Category: Cancer & Oncology Authors: Peng-Bo Deng Juan Jiang Cheng-Ping Hu Li-Ming Cao Min Li Source Type: research
Rapid progression of colonic mucinous adenocarcinoma with immunosuppressive condition: A case report and review of literature
CONCLUSION: While no direct evidence that the immunosuppressants accelerated the tumor development, the case presenta tion and review of the literature demonstrated that surveillance for malignancies before and during treatment with immunosuppressive agents is essential.PMID:34786403 | PMC:PMC8567511 | DOI:10.12998/wjcc.v9.i30.9182
Source: Clinical Colorectal Cancer - November 17, 2021 Category: Cancer & Oncology Authors: Youhei Koseki Kenya Kamimura Yuto Tanaka Marina Ohkoshi-Yamada Qiliang Zhou Yoshifumi Matsumoto Takeshi Mizusawa Hiroki Sato Akira Sakamaki Hajime Umezu Junji Yokoyama Shuji Terai Source Type: research
Metastatic Adenocarcinoma of the Scrotal Skin from an Unknown Primary
Skinmed. 2021 Apr 1;19(2):145-149. eCollection 2021.ABSTRACTA 67-year-old white man presented with a 3-year history of progressively worsening redness and irritation on the suprapubic area, scrotum, and penis. His primary care physician had been treating him unsuccessfully with topical antifungals and corticosteroids during this time. The patient had no significant pain, fever, chills, dysuria, gastrointestinal signs, or a history of sexually transmitted diseases. There was no previous history of malignancy, and his past medical history was not significant beyond an 8 pack-year history of tobacco use that was discontinued ...
Source: Skinmed - May 3, 2021 Category: Dermatology Authors: Julian Stashower Jamison E Strahan Source Type: research
